<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00383370</url>
  </required_header>
  <id_info>
    <org_study_id>VGFT-OD-0603</org_study_id>
    <nct_id>NCT00383370</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD</brief_title>
  <official_title>A Trial to Assess the Safety and Tolerability of Repeated Doses of Intravitreal Administration of Two VEGF Trap Formulations in Subjects With Neovascular Age Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and tolerability of repeated intravitreal (ITV) administration of VEGF
      Trap.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-masked study in which approximately 12 subjects will receive ITV injections of VEGF
      Trap every 4 weeks for a total of 3 doses. Once the subjects have received the 3 doses
      allowed in this study, they will be evaluated every 4 weeks for continued dosing of VEGF Trap
      for an additional 9 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint of the study will be safety and tolerability of the study treatment at Week 12 as assessed by ophthalmic examination and reporting of AEs.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Neovascular Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>ITV-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VEGF Trap formulation 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ITV-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VEGF Trap formulation 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ITV-2 OL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VEGF Trap formulation 2 open label, higher concentration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VEGF Trap</intervention_name>
    <description>VEGF Trap formulation 1, ITV-1</description>
    <arm_group_label>ITV-1</arm_group_label>
    <arm_group_label>ITV-2</arm_group_label>
    <other_name>ITV-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VEGF Trap</intervention_name>
    <description>VEGF Trap formulation 2 at higher concentration in Open label cohort</description>
    <arm_group_label>ITV-2 OL</arm_group_label>
    <other_name>ITV-2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subfoveal CNV secondary to AMD.

          -  Central retinal (including lesion) thickness ≥ 250 µm as measured by OCT.

          -  ETDRS best-corrected visual acuity (BCVA) of 20/40 to 20/400 (73 to 20 letters)

        Exclusion Criteria:

          -  No prior treatment with the following in the study eye:

               -  Subfoveal thermal laser therapy;

               -  Submacular surgery or other surgical intervention for the treatment of AMD;

               -  Extrafoveal laser coagulation treatment within 12 weeks prior to Day 1 (Visit 2);

               -  PDT or ITV administration of triamcinolone acetonide or any other steroid within
                  12 weeks prior to Day 1 (Visit 2);

               -  Pegaptanib sodium within 8 weeks of Day 1 (Visit 2);

               -  Juxtascleral steroids or anecortave acetate within 180 Days (6 months) prior to
                  Day 1 (visit 2);

               -  Prior systemic or intravitreal treatment with VEGF Trap or bevacizumab;

               -  Any investigational agent for the treatment of eye disease within 12 weeks of Day
                  1 (Visit 2)

          -  History of any vitreous hemorrhage within 4 weeks prior to baseline injection visit.

          -  Aphakia or pseudophakia with the absence of a posterior capsule (unless it occurred as
             a result of a yttrium aluminum garnet [YAG] capsulotomy).

          -  Significant subfoveal atrophy or scarring.

          -  Any condition or laboratory abnormality that, in the opinion of the Investigator,
             would interfere with the assessment of disease status/progression or jeopardize the
             subject's appropriate participation in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Avner Ingerman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceutical</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2006</study_first_submitted>
  <study_first_submitted_qc>October 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2006</study_first_posted>
  <last_update_submitted>April 20, 2011</last_update_submitted>
  <last_update_submitted_qc>April 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Avner Ingerman, MD</name_title>
    <organization>Regeneron Pharmaceuticals</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

